Zoetis Drops to 52-Week Low, Monday Open in Focus
Zoetis Inc. closed the week at a fresh 52-week low. Investors now head into the weekend weighing if the animal-health group’s post-earnings slide is done or set to move lower.
Zoetis Stock Plunge: The Pet-Care Slowdown Wall Street Can’t Ignore
Zoetis Inc. slashed its outlook for 2026 profit and revenue, following a first-quarter miss that caught Wall Street off guard—a notable setback for the animal-health firm known for riding premium pet drug demand. Shares slid after Zoetis pointed to U.S. pet owners pulling back on vet appointments and opting out of pricier care.
Zoetis (ZTS) Stock: What to Know Before the Market Opens on Dec. 26, 2025
U.S. stocks return from the Christmas holiday pause with Zoetis Inc. back in focus—not because of an earnings report due today, but because December has brought a cluster of shareholder-return actions, product catalysts, and analyst resets that investors are still digesting heading into the next session.
Zoetis Stock (ZTS) After Hours on Dec. 24, 2025: Price Action, Today’s Headlines, Analyst Forecasts, and What to Watch Before the Next Market Open
Zoetis Inc. wrapped up the Christmas Eve, holiday-shortened session with a solid gain—and then held steady in thin after-hours trading as investors headed into the U.S. market’s Christmas Day shutdown.
Zoetis Stock (ZTS) News Today: $1.75B Convertible Notes, Accelerated Buybacks, Dividend Raise, and Analyst Forecasts (Dec. 17, 2025)
Zoetis Inc. stock is back in focus on Wednesday, December 17, 2025, as investors weigh a fresh analyst update against a flurry of recent corporate actions—most notably a $1.75 billion convertible notes financing designed to fund substantial share repurchases, plus a dividend increase heading into 2026. MarketScreener+2investor.zoetis.com+2
Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights
Zoetis is the global frontrunner in animal health, offering a diverse portfolio for both companion animals and farm animals. The company’s products range from vaccines and parasiticides to dermatology treatments and high-tech diagnostics. This breadth has helped Zoetis capture the #1 industry position – in 2023 its $8.5B in sales exceeded the next-largest competitor by over 50%proclinical.comproclinical.com. Zoetis continues to leverage this scale and innovation engine in 2025, focusing on pet care growth while managing challenges in livestock.